



Psoriatic Arthritis and Sarcopenia: A Cross-Sectional Ultrasonographic Study

ABSTRACT

Background/Aims: This study aims to identify sarcopenia and its associated factors in patients with psoriatic arthritis (PsA) and to assess the diagnostic utility of ultrasonography (USG) for identifying sarcopenia.

Materials and Methods: The study included 54 PsA patients (21 males and 33 females; mean age: 46.5 ± 10.93 ; range, 18-65) and 55 age-, gender- and body mass index (BMI)-matched healthy controls (19 males and 36 females; mean age: 48 ± 11.30 ; range, 18-65). Demographic data, anthropometric measurements, functional assessments, handgrip strength, and 4-meter gait speed were evaluated. Disease activity was evaluated using the psoriatic arthritis impact of disease 12-item questionnaire (PSAID12), disease activity score 28 (DAS28), bath ankylosing spondylitis disease activity index (BASDAI), disease activity in psoriatic arthritis (DAPSA), and skin lesions with the psoriasis area and severity index (PASI). The thickness of bilateral rectus femoris, vastus intermedius, and quadriceps muscle were measured using USG. Whole-body muscle mass was analyzed via dual-energy x-ray absorptiometry.

Results: Sarcopenia was diagnosed in 22 PsA patients (40.7%) and 12 healthy controls (21.8%). An association between sarcopenia, BMI, and disease duration was identified ($P < .05$). It was not associated with PSAID12, DAS28, BASDAI, DAPSA, PASI, age, gender, comorbidities, smoking, alcohol consumption, erythrocyte sedimentation rate, C-reactive protein, vitamin D levels, and history of falls. The USG measurements revealed that PsA patients with sarcopenia had lower thickness of rectus femoris, vastus intermedius, and quadriceps muscles ($P < .05$). Receiver-operating characteristic analysis was performed to determine the diagnostic cut-off values, which were as follows: right/left rectus femoris, 1.11 cm; right vastus intermedius, 1.17 cm; left vastus intermedius, 1.19 cm; right quadriceps, 2.31 cm; left quadriceps, 2.32 cm.

Conclusion: The presence of sarcopenia was higher in PsA patients compared to healthy controls. The USG may be a practical and acceptable method for assessing muscle mass and diagnosing sarcopenia in patients with PsA.

Keywords: Psoriatic arthritis, rheumatic disease, sarcopenia, ultrasonography

Introduction

Psoriatic arthritis (PsA) is a chronic inflammatory disorder that presents with a wide range of clinical features, including both peripheral and axial joint involvement, enthesitis, dactylitis, and characteristic skin and nail changes, all of which may contribute to considerable disability.¹

Gonca Canan Doğan
Tosun¹

Tuba Güler¹

Fatma Gül Yurdakul¹

Hatice Bodur²

Mehtap Balaban²

¹Ankara City Hospital, Physical Medicine and Rehabilitation Hospital, Ankara, Türkiye
²Yıldırım Beyazıt University Faculty of Medicine, Ankara City Hospital Physical Medicine and Rehabilitation Hospital, Ankara, Türkiye

Corresponding author:
Tuba Güler
✉ tubakulu@yahoo.com

Received: January 23, 2025
Revision Requested: March 17, 2025
Last Revision Received: June 18, 2025
Accepted: July 7, 2025
Publication Date: September 1, 2025

Cite this article as: Tosun GCD, Güler T, Yurdakul FG, Bodur H, Balaban M. Psoriatic arthritis and sarcopenia: A cross-sectional ultrasonographic study. *Arch Rheumatol.* 2025;40(3):315-322.



Sarcopenia is a chronic neuromuscular disorder associated with aging. It is defined by a progressive decline in skeletal muscle mass (SMM) and function, accompanied by impaired physical performance. This condition is marked by reduced mobility and is linked to an increased risk of adverse clinical outcomes, including higher rates of morbidity and all-cause mortality.² Although sarcopenia is commonly associated with aging; immobilization, malnutrition, and chronic diseases can also contribute to its development.³ Muscle loss due to chronic diseases is more progressive compared to age-related muscle loss.⁴ Sarcopenia is diagnosed based on the evaluation of muscle mass. Methods such as ultrasonography (USG), bioelectrical impedance analysis, dual-energy X-ray absorptiometry (DEXA), computed tomography, and magnetic resonance imaging (MRI) are employed to assess muscle mass. Once sarcopenia is confirmed, physical performance assessments such as gait speed, the short physical performance battery, and the timed up and go test are used to identify severe sarcopenia.⁵

Muscle USG has emerged as a new method for the diagnosis of sarcopenia. Regardless of the diagnostic criteria, measurement of muscle mass remains a cornerstone in the diagnosis of sarcopenia. Owing to its safety, non-invasiveness, low cost, and real-time capability, USG has gained increasing prominence as a tool for muscle mass measurement. The USG is considered a highly reproducible, accurate, and reliable method for measuring muscle mass.⁶ In a meta-analysis conducted by Fu et al,⁷ lower extremity muscle thickness was evaluated as a common parameter for diagnosing sarcopenia using USG.

Although sarcopenia has been investigated in various chronic inflammatory conditions, studies specifically involving PsA patients remain scarce. Most of the current USG literature pertains to individuals with rheumatoid arthritis (RA), with limited evidence available on its application for assessing sarcopenia in PsA. This study is therefore of particular significance, as it represents the first to employ USG in evaluating sarcopenia in patients with PsA.

MAIN POINTS

- *The presence of sarcopenia was higher in PsA patients compared to healthy controls.*
- *Sarcopenia showed a statistically significant association with both BMI and disease duration in PsA patients.*
- *Ultrasonographic measurements demonstrated reduced rectus femoris, vastus intermedius, and quadriceps muscle thickness in PsA patients with sarcopenia.*
- *USG may be a practical and acceptable method for assessing muscle mass and diagnosing sarcopenia in patients with PsA.*

Methods

Study Design

This cross-sectional case-control study was performed between September 2022 and September 2023 at Ankara City Hospital Physical Therapy and Rehabilitation. The study was conducted following approval from the Ethics Committee for Clinical Research of the University of Health Sciences (Approval date: September 14, 2022; Approval number: E2-22-2238) and in compliance with the principles outlined in the Declaration of Helsinki. Each individual voluntarily signed a written consent form before being enrolled in the study.

Participants

A total of 109 participants took part in the study. Among them, 54 patients (21 males, 33 females; mean age: 46.5 ± 10.93 years), aged between 18 and 65 years, had been diagnosed with PsA in accordance with the CASPAR criteria at least 1 year earlier and had experienced no modifications to their therapeutic regimen within the preceding 3 months. The control group consisted of 55 age, gender, and body mass index (BMI)-matched healthy individuals. The exclusion criteria included the following: (1) individuals with neurological diseases; (2) hip dislocation; (3) upper and lower extremity deformities; (4) joint arthroplasty in the upper and lower extremities; (5) lumbar stabilization; (6) cognitive impairments preventing participation; (7) participants exceeding 100 kg in body weight were excluded from the study due to the device's maximum measurable weight limit; and (8) individuals who did not consent to participate.

Clinical Assessment

Demographic data of the patients (age, gender, education level, occupation, and marital status), medication use, history of rheumatological disease, time of PsA diagnosis, disease duration, and presence of chronic disease were recorded. Additionally, smoking status, weight, height, BMI, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), vitamin D levels, and history of falls were documented.

Anthropometric Assessment

Anthropometric measurements of PsA patients and healthy controls (mid-upper arm circumference of both arms and the largest circumference of both calves) were performed.

Height and weight were documented for all participants in both groups, and BMI values were computed accordingly.

Muscle Strength Assessment

Handgrip strength was assessed with a Jamar hydraulic hand dynamometer (FEI®, model 5030J1, USA) with the participant positioned in shoulder adduction, elbow at 90 degrees of flexion, and the forearm and wrist in a neutral, supported position.⁸ A study conducted by Gulistan Bahat et al⁹ in 2016 aimed to define reference cut-off

values for the Turkish population to improve the general applicability of EWGSOP criteria. The study found handgrip strength cut-off values for sarcopenia to be 32 kg for males and 22 kg for females. In the present study, handgrip strength below 32 kg for males and 22 kg for females was considered reduced handgrip strength.

Physical Performance Assessment

A 4-meter gait speed test (including 1 meter acceleration, 4-meter walking area, and 1 meter deceleration area) was used to assess physical performance in both groups. A walking speed of <0.8 m/s was interpreted as impaired physical function.¹⁰

Muscle Mass Assessment

To assess muscle mass in both groups, quadriceps muscle thickness of the dominant and non-dominant limbs was measured using a Logiq 9 ultrasound device (GE, USA) with a high-frequency 7-12 MHz linear probe. Muscle thickness was measured bilaterally in the distal 1/3 of the distance between the superior anterior iliac spine and the superior pole of the patella in a seated position. Axial images were recorded after ensuring no compression on subcutaneous fat and muscle tissue.

Whole-body muscle mass was assessed using DEXA measurement results obtained from previously conducted scans (Lunar iDEXA; GE Healthcare, 3030 Ohmeda Drive, Madison, WI 53718). Appendicular skeletal muscle mass (ASM) was first calculated, and the SMM index (SMMI) was then derived using the $ASM/height^2$ formula. An SMMI value below 7.4 for females and 9.2 for males was considered significant.⁹

Assessment of Activities of Daily Living, Balance-Gait, and Psychosocial Characteristics

Sarcopenia quality of life questionnaire (SarQoL) consisting of 55 items in 22 questions,¹¹ Tinetti balance and gait test,¹² and the hospital anxiety and depression scale¹³ were administered to both groups.

Assessment of Disease Activity

Disease activity in patients with PsA was evaluated using the psoriatic arthritis impact of disease 12-item questionnaire,¹⁴ disease activity score 28 (DAS28),¹⁵ bath ankylosing spondylitis disease activity index (BASDAI),¹⁶ and disease activity in psoriatic arthritis (DAPSA)¹⁷ as well as skin lesions with the psoriasis area and severity index (PASI).¹⁸

Statistical Analysis

Sample size estimation and power calculation were executed using G*Power software version 3.1.9.4 (Heinrich Heine University, Düsseldorf, Germany). The analysis indicated that at least 53 individuals per group (total $n=106$) were necessary to achieve a statistical power of 0.80. IBM SPSS Statistics for Windows version 23.0 (IBM SPSS Corp.; Armonk, NY, USA) was used for data analysis. Normal distribution of numerical data was examined using the Kolmogorov-Smirnov test. General descriptive

statistics were presented as mean, median, standard deviation, minimum, and maximum values for continuous variables, and as count and percentage (%) for categorical variables. Categorical variables were compared using the Chi-square test or Fisher's exact test, and continuous variables were analyzed using the Student's *t*-test or Mann-Whitney *U* test based on data distribution. The relationship between ultrasonographic muscle thickness and SMMI was analyzed using Pearson correlation analysis. The receiver-operating characteristic (ROC) curve analysis was performed to calculate cut-off values for sarcopenia-related thickness of the right and left rectus femoris, vastus intermedius, and quadriceps muscles. All analyses were conducted with a 95% CI, and statistical significance was defined as $P < .05$.

Results

A total of 109 participants were included in this study, consisting of 54 PsA patients (mean age: 46.5 ± 10.93 years) and 55 healthy controls (mean age: 48 ± 11.30 years). Table 1 summarizes the demographic characteristics of the participants. There were no statistically significant differences between the groups regarding age, gender, occupation, or education.

The average disease duration of PsA patients was 10.24 ± 10.28 years. Axial involvement was present in 24 patients (44%), while oligoarticular involvement was observed in 30 patients (56%). A total of 29 patients were found to use conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), 11 patients were using biological DMARDs, 3 patients were taking a combination of csDMARDs and bDMARDs, 7 patients were taking only NSAIDs, and 1 patient was taking only steroids. Based on DAPSA scores, 3.7% of patients ($n=2$) were classified as being in remission, while 24.2% ($n=13$) exhibited low, 33.3% ($n=18$) moderate, and 38.8% ($n=21$) high levels of disease activity. According to BASDAI, 37 (68.5%) patients were classified as having active disease.

Functional assessments were conducted in both the PsA group and healthy controls. The PsA patients exhibited lower dominant and non-dominant handgrip strength, reduced 4-meter gait speed, decreased SarQoL scores, and smaller right calf circumference in comparison to the healthy control group ($P < .05$).

While the difference in Tinetti balance test scores between the 2 groups was not statistically significant, the Tinetti gait test scores were lower in the PsA patient group ($P < .05$). No statistically significant differences were observed between the 2 groups in terms of the hospital anxiety and depression scale results (Table 2).

Sarcopenia was diagnosed in 22 PsA patients (40.7%) and 12 healthy controls (21.8%) based on the SMMI cut-off value⁹ ($P < .05$). Associations between sarcopenia and clinical variables were analyzed. There was no meaningful association identified between sarcopenia and variables

Table 1. Demographic Characteristics of Psoriatic Arthritis Patients and Control Group

	PsA	Control	P
Age, years, mean ± SD	46.5 ± 10.9	48 ± 11.3	.956
Gender, n (%)			
Female	33 (61.1)	36 (65.5)	.638
Male	21 (38.9)	19 (34.5)	
Body mass index, kg/m ² , mean ± SD	29.0 ± 5.7	27.3 ± 4.7	.094
Occupation, n (%)			
Office worker	22 (40.7)	29 (52.7)	.504
Worker	7 (13)	8 (14.5)	
Housewife	22 (40.7)	15 (27.3)	
Retired	3 (5.6)	3 (5.5)	
Education, n (%)			
Primary school	17 (31.5)	16 (29.1)	.886
Secondary school	5 (9.3)	3 (5.5)	
High school	13 (24.1)	16 (29.1)	
Associate degree	3 (5.6)	2 (3.6)	
License	16 (29.6)	18 (32.7)	
Dominant hand, n (%)	54 (100)	55 (100)	–
Smoking, n (%)			
Never	29 (53.7)	39 (70.9)	.176
Active	23 (42.6)	15 (27.3)	
Ex-smoker	2 (3.7)	1 (1.8)	
Cigarettes (pack/year) median (min-max)	0 (0-40)	0 (0-35)	.191
Alcohol consumption, n (%)			
Yes	4 (7.4)	5 (9.1)	.573
No	50 (92.6)	55 (90.9)	
Comorbidity, n (%)			
Yes	33 (61.1)	22 (40)	.028
No	21 (38.9)	33 (60)	
Comorbidity, n (%)			
No	21 (36.6)	32 (58.2)	.195
HT	10 (17.4)	10 (18)	
DM	1 (1.9)	1 (1.8)	
The history of CAD	3 (5.2)	1 (1.8)	
Hypothyroidism	4 (7.4)	5 (9.1)	
HT + DM	3 (5.6)	1 (1.8)	
Other	12 (25.9)	5 (9.1)	
Vitamin D, median (min-max), nmol/L	30 (8.5-92)	33 (6-98)	.132

Of the data, the normally distributed ones were given as ± SD and the non-normally distributed ones were given as median (min-max). *P* < .05 was considered significant.
BMI, body mass index; CAD, coronary artery disease; DM, diabetes mellitus; HT, hypertension; PsA, psoriatic arthritis.

such as age, gender, comorbidities, smoking, alcohol consumption, disease activity, ESR, CRP, vitamin D levels, or history of falls. However, sarcopenia was found to be associated with BMI and disease duration (*P* = .025, *P* = .017, respectively) (Table 3).

The quadriceps muscle thickness measurements were lower in sarcopenic PsA patients while there were no statistically significant differences in subcutaneous tissue between sarcopenic and non-sarcopenic individuals (Table 4).

The ultrasonographic muscle thickness of the right and left vastus intermedius and quadriceps showed a positive correlation with SMMI (*r*=0.444, *P* < .001; *r* = 0.463, *P* < .001; *r* = 0.364, *P* = .007; *r* = 0.369, *P* = .006, respectively). The correlation between SMMI and both disease duration and BMI was also examined. For BMI and SMMI, *r*=0.675, *P* < .001; for disease duration and SMMI, *r*=0.318, *P*=.318.

The ROC analysis was employed to assess the diagnostic performance of muscle thickness measurements in identifying sarcopenia. Results of ROC analysis for ultrasonographic muscle thickness are presented in Table 5. The cut-off value for the right and left rectus femoris muscle thickness was determined to be 1.11 cm (sensitivity was 57%, and specificity was 60%). The cut-off value for the right vastus intermedius muscle thickness was 1.17 cm, (sensitivity of 61% and specificity of 62%). For the left vastus intermedius muscle thickness, the cut-off value was 1.19 cm, with a sensitivity of 63% and specificity of 62%. The cut-off value for the right quadriceps muscle thickness was determined to be 2.31 cm, with a sensitivity of 68% and specificity of 69%. For the left quadriceps muscle thickness, the cut-off value was 2.32 cm, with a sensitivity of 68% and specificity of 62%. The results of the ROC analysis are shown in Figure 1.

Discussion

In this study investigating sarcopenia in patients with PsA, the presence of sarcopenia was found to be 40.7% among PsA patients compared to 21.8% in healthy controls. A significant association was observed between sarcopenia and both BMI and disease duration. However, no statistically significant correlations were observed with age, gender, disease activity, comorbidities, history of falls, smoking status, alcohol consumption, or vitamin D levels. Diagnostic cut-off values for the thickness of the rectus femoris, vastus intermedius, and quadriceps muscles were established through ROC curve analysis.

The number of studies exploring sarcopenia in PsA is limited. Existing research has reported the prevalence of sarcopenia to be between 9.1% and 49% in individuals with PsA.¹⁹⁻²¹ In studies examining inflammatory diseases and sarcopenia, the prevalence has been found to be between 7.8% and 39.8% in patients with RA,^{19,20,22-24} and between 1.7% and 61.7% in those with spondyloarthritis (SpA).^{19,25,26} The differences in reported sarcopenia rates across studies can be attributed to variations in the criteria, evaluation methods, and sample sizes used in each study.

In this study, sarcopenia in PsA patients was found to be associated with disease duration. However, the literature presents conflicting evidence on this relationship. For instance, Barone et al²⁰ and the SASPAR study²⁵ reported no association between disease duration and sarcopenia in PsA and SpA patients, respectively. Conversely, a meta-analysis²⁷ and comprehensive review²⁸ demonstrated a link between disease duration and sarcopenia in RA

Table 2. Functional Assessments of Patients with Psoriatic Arthritis and Control Group

	PsA	Control	P
Muscle strength (handgrip strength)			
Dominant hand median (min-max)	20 (2-70)	30 (10-50)	.004
Non-dominant hand median (min-max)	20 (2-70)	25 (10-48)	<.001
4-meter gait speed test median (min-max) (m/s)	1.1 (0.50-2.50)	1.4 (0.67-2.34)	.004
SARQoL test (mean ± SD)	60.1 ± 15.8	75.9 ± 13.9	<.001
Tinetti			
Balance test median (min-max)	26 (17-29)	26 (23-26)	.147
Gait test median (min-max)	9 (6-9)	9 (9-9)	.041
Depression-anxiety scale median (min-max)			
Depression scale median (min-max)	5 (0-20)	5 (0-16)	.342
Anxiety scale median (min-max)	7.5 (1-19)	5 (0-17)	.078

From the data, the normally distributed ones were given as ± SD and the normally distributed ones were given as median (min-max). *P* < .05 was considered significant.
PsA, psoriatic arthritis; SARQoL, sarcopenia quality of life questionnaire.

patients. Similarly, Torii et al²⁴ identified disease duration as a factor associated with sarcopenia in RA. Aligning with these findings, the present study confirms the association, likely reflecting prolonged exposure to systemic chronic inflammation.

The present study identified a significant association between low BMI and sarcopenia, corroborating earlier research reporting comparable findings.^{22,23} Taken together, the evidence emphasizes the crucial contribution of undernutrition and malnutrition to the onset of sarcopenia.

As part of the current study, no relevant link was identified between sarcopenia and indicators of disease activity, including PSAID-12, DAS28, DAPSA, BASDAI, and PASI. There is currently no other study in the literature that has investigated the relationship between disease activity and sarcopenia in individuals with PsA. However, findings on this relationship remain inconsistent in studies involving RA and SpA. In the SASPAR study,²⁵ BASDAI was found to be associated with sarcopenia. Mochizuki et al²² reported no significant association between DAS28-ESR and sarcopenia in patients with RA. In the meta-analysis²⁷ DAS28 values were emphasized to be associated with sarcopenia in RA patients. In this study, the absence of an association between sarcopenia and disease activity may be attributed to the cross-sectional evaluation of disease activity.

Research interest in the link between sarcopenia and rheumatic diseases has grown substantially in recent years. Chronic inflammatory activity is believed to be a key mechanism, with pro-inflammatory cytokines contributing to impaired skeletal muscle function, disrupted protein synthesis, and loss of muscle mass.²⁹ Tumor necrosis factor- α , a key cytokine involved in PsA, drives inflammation in the synovium, entheses, and bone, and is also implicated in muscle aging and the development of sarcopenia.²⁹ Likewise, prolonged elevation of interleukin-6 has been shown to promote muscle

wasting, trigger catabolic pathways, and reduce muscle strength.³⁰ It has been proposed that biological DMARD therapy may exert a protective role against the onset of sarcopenia.³¹ Torii et al²⁴ reported a negative correlation between bDMARDs treatment and sarcopenia. However, Barone et al²⁰ argued that biologic therapy does not have a protective effect against sarcopenia. In the meta-analysis by Hein et al,³² which evaluated the impact of DMARDs on muscle mass in individuals with RA, no significant influence of DMARD use on muscle mass was observed. In this study, neither anti-TNF agents nor other biologic therapies demonstrated a statistically significant impact on sarcopenia. Additional research is needed to better elucidate this association.

In the present study, no association was found between sarcopenia and gender. While some studies have reported higher rates of sarcopenia in males^{20,25} others have identified a greater prevalence in females.²⁶ However, limited data restricts a definitive conclusion on the gender-sarcopenia relationship. Similarly, no link was observed between vitamin D levels and sarcopenia in our study. Minamino et al,³³ in a study of female patients with RA, found that low vitamin D levels were associated with severe sarcopenia, reduced muscle mass, weaker grip strength, and slower gait speed. In contrast, most participants in the current study had either completed or were receiving vitamin D supplementation, which may explain the absence of a significant association.

In the present study, USG was employed to assess the bilateral muscle thickness of the rectus femoris, vastus intermedius, as well as the total quadriceps thickness. The analysis demonstrated that individuals diagnosed with sarcopenia exhibited a markedly reduced thickness across all 3 muscle groups compared to healthy controls. The area under the ROC curve and the corresponding cut-off values for rectus femoris thickness were identical bilaterally, measured at 1.11 cm for both the right and left legs. For the vastus intermedius, the cut-off thresholds were 1.17 cm on the right side and 1.19 cm on the

Table 3. Variables Associated with Sarcopenia in Sarcopenic Patients with Psoriatic Arthritis

	Sarcopenia	Non-Sarcopenia	P
Age (mean ± SD)	44.2 ± 11.5	46.6 ± 10.5	.433
Gender n (%)	22 (40.7)	32 (59.3)	
Female	15 (68.2)	18 (56.3)	.377
Male	7 (31.8)	14 (43.8)	
BMI (mean ± SD)	26.4 ± 3.5	30.7 ± 6.3	.025
Comorbidity			
Yes	15 (68.2)	18 (56.3)	.377
No	7 (31.8)	14 (43.8)	
Smoking n (%)			
Never	12 (45.5)	13 (40.6)	.484
Active	10 (54.5)	17 (53.1)	
Ex-smoker	0 (0)	0 (0)	
Cigarettes (packs/year) med (min-max)	0.0 (0-40)	0.0 (0-30)	.822
Alcohol consumption n (%)			
Yes	1 (4.5)	3 (9.4)	.506
No	21 (95.5)	29 (90.6)	
Disease duration median (min-max) (years)	10.5 (1-35)	4 (1-50)	.017
Medication n (%)			
bDMARDs-TNF-α inhibitors	5 (22.7)	8 (25.0)	.310
non-TNF-α bDMARDs	–	3 (9.4)	
csDMARDs/NSAID/corticosteroid	17 (77.3)	21 (65.6)	
DAS-28 (mean ± SD)	3.6 ± 1.1	3.2 ± 1.2	.267
DAPSA (mean ± SD)	31.3 ± 21.9	25.2 ± 20.1	.190
BASDAI (mean ± SD)	5.7 ± 2.2	4.8 ± 2.6	.218
PSAID-12 (mean ± SD)	4.7 ± 2.4	4.3 ± 2.1	.567
PASI median (min-max)	0 (0-32.4)	1.5 (0-21.9)	.085
ESR median (min-max) (mm/h)	11.5 (1-45)	7.5 (3-31)	.132
CRP median (min-max) (mg/dL)	4 (0-61)	3 (0-32)	.101
Vitamin D median (min-max) (nmol/L)	39 (14.2-82)	29 (8.5-92)	.452
History of falls n (%)			
Yes	4 (18.2)	5 (15.6)	.804
No	18 (81.8)	27 (84.4)	
Right calf circumference (mean ± SD)	35.8 ± 3.1	37.9 ± 3.8	.049

From the data, the normally distributed ones were given as ± SD and the normally distributed ones were given as median (min-max). *P* < .05 was considered significant.
BASDAI, bath ankylosing spondylitis disease activity index; bDMARDs, biologic disease-modifying antirheumatic drugs; BMI, body mass index (kg/m²); CRP, C-reactive protein (mg/dL); csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; DAS-28, disease activity score; DAPSA, disease activity in psoriatic arthritis; ESR, erythrocyte sedimentation rate (mm/h); NSAID, non-steroidal anti-inflammatory drug; PASI, psoriasis area severity index; PSAID-12, psoriatic arthritis impact of disease 12-item questionnaire; TNF, tumor necrosis factor.

left. Meanwhile, the quadriceps muscle exhibited cut-off values of 2.31 cm on the right and 2.32 cm on the left. These findings align with existing literature. In a study conducted by Tada et al,³⁴ ultrasound-based assessment of thigh muscle and adipose tissue thickness in patients with RA demonstrated a significant reduction in quadriceps thickness among sarcopenic individuals. Similarly, Salaffi et al³⁵ reviewed the utility of ultrasound and MRI in detecting sarcopenia within immune-mediated rheumatic diseases, reporting that RA patients exhibited decreased vastus lateralis fascicle thickness and length compared to healthy controls. Furthermore, Dos Santos et al³⁶ employed ultrasound-based assessment of

quadriceps thickness in RA patients, revealing not only reduced muscle thickness but also concomitant declines in muscle strength.

This study has several limitations, including its cross-sectional design and relatively small sample size. Future longitudinal studies with larger cohorts are warranted to further elucidate the relationship between PsA and sarcopenia.

A key strength of this study is the novel application of USG to evaluate sarcopenia in patients with PsA, which is expected to contribute meaningfully to the current literature.

Table 4. USG Measurements of Sarcopenic and Non-Sarcopenic Psoriatic Arthritis Patients

USG Thickness Measurements (cm)	Sarcopenia	Non-Sarcopenia	P
Right subcutaneous tissue (mean ± SD)	0.97 ± 0.35	1.00 ± 0.54	.826
Left subcutaneous tissue (mean ± SD)	0.99 ± 0.98	1.00 ± 0.52	.666
Right rectus femoris (mean ± SD)	1.06 ± 0.28	1.27 ± 0.37	.040
Left rectus femoris (mean ± SD)	1.01 ± 0.31	1.29 ± 0.39	.006
Right vastus intermedius (mean ± SD)	1.11 ± 0.31	1.31 ± 0.37	.048
Left vastus intermedius (mean ± SD)	1.15 ± 0.32	1.35 ± 0.34	.028
Right quadriceps (mean ± SD)	2.17 ± 0.52	2.59 ± 0.63	.016
Left quadriceps (mean ± SD)	2.17 ± 0.59	2.64 ± 0.60	.004

From the data, the normally distributed ones were given as ± SD and the normally distributed ones were given as median (min-max). $P < .05$ was considered significant

USG, ultrasonography.

Values with $P < 0.05$ are indicated in bold


To conclude, the findings of this study highlight that sarcopenia is more prevalent among individuals with PsA. In patients with PsA, sarcopenia was significantly associated with BMI and disease duration. Ultrasonographic assessments revealed that the sarcopenic group exhibited notably reduced thickness of the rectus femoris, vastus intermedius, and quadriceps muscles. The ROC analyses identified specific cut-off values for these muscle groups, supporting their diagnostic relevance. Given its accessibility, safety, and ease of application, USG may be considered a practical and

Table 5. ROC Analysis Result of Ultrasonographic Muscle Thickness

USG thickness measurements (cm)	Area	Standard Error	P	CI (95%)	
				Lower Bound	Upper Bound
Right rectus femoris	0.680	0.053	.001	0.575	0.784
Left rectus femoris	0.672	0.052	.001	0.570	0.773
Right vastus intermedius	0.697	0.050	<.001	0.598	0.795
Left vastus intermedius	0.691	0.050	<.001	0.594	0.788
Right quadriceps	0.731	0.049	<.001	0.634	0.827
Left quadriceps	0.716	0.048	<.001	0.622	0.811

$P < .05$ was considered significant

USG, ultrasonography.

**Figure 1.** Diagonal segments are produced by ties.

supportive modality for the assessment of sarcopenia in clinical settings.

Data Availability Statement: The data that support the findings of this study are available on request from the corresponding author.

Ethics Committee Approval: This study was approved by the Ethics Committee of University of Health Sciences, Ankara City Hospital Clinical Research Ethics Committee (Approval no: E2-22-2238; Date: September 14, 2022).

Informed Consent: Written informed consent was obtained from the patients who agreed to take part in the study.

Peer-review: Externally peer-reviewed.

Author Contributions: Concept – G.C.D.T., T.G., H.B.; Design – G.C.D.T., T.G., H.B., F.G.; Supervision – T.G., H.B., F.G.Y.; Resources – G.C.D.T., T.G., H.B., M.B.; Materials – G.C.D.T., T.G., H.B., M.B.; Data Collection and/or Processing – G.C.D.T.; Analysis and/or Interpretation – F.G.Y., T.G.; Literature Search – G.C.D.T., T.G.; Writing – G.C.D.T., T.G.; Critical Review – H.B., F.G.Y., T.G.

Declaration of Interests: Fatma Gül Yurdakul is an Associate Editor at the Archives of Rheumatology, however, her involvement in the peer review process was solely as an author. The other authors have no conflicts of interest to declare.

Funding: The authors declare that this study received no financial support.

References

- Nas K, Kiliç E, Çevik R, et al. Management of psoriatic arthritis: Turkish league against rheumatism (TLAR) expert opinions. *Arch Rheumatol*. 2018;33(2):108-127. [\[CrossRef\]](#)
- Sayer AA, Cruz-Jentoft A. Sarcopenia definition, diagnosis and treatment: consensus is growing. *Age Ageing*. 2022;51(10):afac220. [\[CrossRef\]](#)

3. Moschou D, Krikelis M, Georgakopoulos C, et al. Sarcopenia in rheumatoid arthritis. A narrative review. *J Frailty Sarcopenia Falls*. 2023;8(1):44-52. [\[CrossRef\]](#)
4. Bauer J, Morley JE, Schols AMWJ, et al. Sarcopenia: a time for action. An SCWD position paper. *J Cachexia Sarcopenia Muscle*. 2019;10(5):956-961. [\[CrossRef\]](#)
5. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. *Age Ageing*. 2019;48(1):16-31. [\[CrossRef\]](#)
6. Perkisas S, Bastijns S, Baudry S, et al. Application of ultrasound for muscle assessment in sarcopenia: 2020 SARCUS update. *Eur Geriatr Med*. 2021;12(1):45-59. [\[CrossRef\]](#)
7. Fu H, Wang L, Zhang W, Lu J, Yang M. Diagnostic test accuracy of ultrasound for sarcopenia diagnosis: a systematic review and meta-analysis. *J Cachexia Sarcopenia Muscle*. 2023;14(1):57-70. [\[CrossRef\]](#)
8. Vermeulen J, Neyens JC, Spreeuwenberg MD, van Rossum E, Hewson DJ, de Witte LP. Measuring grip strength in older adults: comparing the grip-ball with the Jamar dynamometer. *J Geriatr Phys Ther*. 2015;38(3):148-153. [\[CrossRef\]](#)
9. Bahat G, Tufan A, Tufan F, et al. Cut-off points to identify sarcopenia according to European Working Group on Sarcopenia in Older People (EWGSOP) definition. *Clin Nutr*. 2016;35(6):1557-1563. [\[CrossRef\]](#)
10. Maggio M, Ceda GP, Ticinesi A, et al. Instrumental and non-instrumental evaluation of 4-meter walking speed in older individuals. *PLoS One*. 2016;11(4):e0153583. [\[CrossRef\]](#)
11. Beaudart C, Biver E, Reginster JY, et al. Development of a self-administrated Quality of Life Questionnaire for sarcopenia in elderly subjects: the SarQoL. *Age Ageing*. 2015;44(6):960-966. [\[CrossRef\]](#)
12. Köpke S, Meyer G. The Tinetti test: Babylon in geriatric assessment. *Z Gerontol Geriatr*. 2006;39(4):288-291. [\[CrossRef\]](#)
13. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. *J Psychosom Res*. 2002;52(2):69-77. [\[CrossRef\]](#)
14. Güler T, Bora Karslı P, Ataman Ş, Bodur H. Psoriatic arthritis impact of disease questionnaire: validity, reliability and its clinical potential. *Rheumatol Int*. 2020;40(6):959-967. [\[CrossRef\]](#)
15. Wells G, Becker JC, Teng J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. *Ann Rheum Dis*. 2009;68(6):954-960. [\[CrossRef\]](#)
16. Akkoc Y, Karatepe AG, Akar S, Kirazlı Y, Akkoc N. A Turkish version of the Bath Ankylosing Spondylitis Disease Activity Index: Reliability and validity. *Rheumatol Int*. 2005;25(4):280-284. [\[CrossRef\]](#)
17. Schoels M, Aletaha D, Funovits J, Kavanaugh A, Baker D, Smolen JS. Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. *Ann Rheum Dis*. 2010;69(8):1441-1447. [\[CrossRef\]](#)
18. Chandran V, Gottlieb A, Cook RJ, et al. International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis. *Arthritis Rheum*. 2009;61(9):1235-1242. [\[CrossRef\]](#)
19. Tournadre A, Jaffeux P, Frayssac T, et al. SAT0682 Prevalence of sarcopenia in patients with chronic inflammatory rheumatic diseases. *Ann Rheum Dis*. 2017;76:1033-1033. [\[CrossRef\]](#)
20. Barone M, Viggiani MT, Anelli MG, et al. Sarcopenia in patients with rheumatic diseases: prevalence and associated risk factors. *J Clin Med*. 2018;7(12):504. [\[CrossRef\]](#)
21. Krajewska-Włodarczyk M, Owczarczyk-Saczonek A, Placek W. Changes in body composition and bone mineral density in postmenopausal women with psoriatic arthritis. *Reumatologia*. 2017;55(5):215-221. [\[CrossRef\]](#)
22. Mochizuki T, Yano K, Ikari K, Okazaki K. Sarcopenia-associated factors in Japanese patients with rheumatoid arthritis: a cross-sectional study. *Geriatr Gerontol Int*. 2019;19(9):907-912. [\[CrossRef\]](#)
23. Ngeuleu A, Allali F, Medrare L, Madhi A, Rkain H, Hajjaj-Hasouni N. Sarcopenia in rheumatoid arthritis: prevalence, influence of disease activity and associated factors. *Rheumatol Int*. 2017;37(6):1015-1020. [\[CrossRef\]](#)
24. Torii M, Hashimoto M, Hanai A, et al. Prevalence and factors associated with sarcopenia in patients with rheumatoid arthritis. *Mod Rheumatol*. 2019;29(4):589-595. [\[CrossRef\]](#)
25. Merle B, Cottard M, Sornay-Rendu E, Szulc P, Chapurlat R. Spondyloarthritis and sarcopenia: prevalence of probable sarcopenia and its impact on disease burden: the Saspar study. *Calcif Tissue Int*. 2023;112(6):647-655. [\[CrossRef\]](#)
26. Aguiar R, Sequeira J, Meirinhos T, Ambrósio C, Barcelos A. SARCOSPA – Sarcopenia in spondyloarthritis patients. *Acta Rheumatol Port*. 2014;39(4):322-326.
27. Li TH, Chang YS, Liu CW, et al. The prevalence and risk factors of sarcopenia in rheumatoid arthritis patients: a systematic review and meta-regression analysis. *Semin Arthritis Rheum*. 2021;51(1):236-245. [\[CrossRef\]](#)
28. An HJ, Tizaoui K, Terrazzino S, et al. Sarcopenia in autoimmune and rheumatic diseases: a comprehensive review. *Int J Mol Sci*. 2020;21(16):5678. [\[CrossRef\]](#)
29. Pan L, Xie W, Fu X, et al. Inflammation and sarcopenia: a focus on circulating inflammatory cytokines. *Exp Gerontol*. 2021;154:111544. [\[CrossRef\]](#)
30. Bano G, Trevisan C, Carraro S, et al. Inflammation and sarcopenia: a systematic review and meta-analysis. *Maturitas*. 2017;96:10-15. [\[CrossRef\]](#)
31. Wu J, Lin S, Chen W, et al. TNF- α contributes to sarcopenia through caspase-8/caspase-3/GSDME-mediated pyroptosis. *Cell Death Discov*. 2023;9(1):76. [\[CrossRef\]](#)
32. Hein TR, Peterson L, Bartikoski BJ, Portes J, Espírito Santo RC, Xavier RM. The effect of disease-modifying anti-rheumatic drugs on skeletal muscle mass in rheumatoid arthritis patients: a systematic review with meta-analysis. *Arthritis Res Ther*. 2022;24(1):171. [\[CrossRef\]](#)
33. Minamino H, Katsushima M, Torii M, et al. Serum vitamin D status inversely associates with a prevalence of severe sarcopenia among female patients with rheumatoid arthritis. *Sci Rep*. 2021;11(1):20485. [\[CrossRef\]](#)
34. Tada M, Yamada Y, Mandai K, Hidaka N. Screening for sarcopenia and obesity by measuring thigh muscle and fat thickness by ultrasound in patients with rheumatoid arthritis. *Osteoporos Sarcopenia*. 2021;7(2):81-87. [\[CrossRef\]](#)
35. Salaffi F, Carotti M, Di Matteo A, et al. Ultrasound and magnetic resonance imaging as diagnostic tools for sarcopenia in immune-mediated rheumatic diseases (IMRDs). *Radiol Med*. 2022;127(11):1277-1291. [\[CrossRef\]](#)
36. Dos Santos LP, do Espírito Santo RC, Pena É, et al. Morphological parameters in quadriceps muscle were associated with clinical features and muscle strength of women with rheumatoid arthritis: a cross-sectional study. *Diagnostics (Basel)*. 2021;11(11):2014. [\[CrossRef\]](#)